The FDA doesnt have guidelines for microdosing GLP-1 medications and there is a lack of research about the safety and effectiveness of the practice
the exact sourcing model and pharmaceutical classification (503A vs
Renal function must be considered, as some GLP-1 agents require dose adjustment or have limitations in advanced chronic kidney disease
Accessed 12/6/2022, Warren B, Fenton GE, Klenschi E, Windmill JFC, French AS
Evidence of a bi-directional relationship between heart failure and diabetes: A strategy for the detection of glucose abnormalities and diabetes prevention in patients with heart failure
They include nausea (35.5%), diarrhea (21.1%), constipation (20.7%), and stomach pain